While Sarepta Therapeutics Inc has overperformed by 1.77%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SRPT fell by -50.49%, with highs and lows ranging from $173.25 to $48.01, whereas the simple moving average fell by -46.54% in the last 200 days.
On April 11, 2025, Wells Fargo started tracking Sarepta Therapeutics Inc (NASDAQ: SRPT) recommending Overweight. A report published by H.C. Wainwright on April 02, 2025, Upgraded its rating to ‘Neutral’ for SRPT. RBC Capital Mkts also Downgraded SRPT shares as ‘Sector Perform’, setting a target price of $87 on the company’s shares in a report dated March 31, 2025. Deutsche Bank Initiated an Hold rating on February 11, 2025, and assigned a price target of $136. Needham resumed its ‘Buy’ rating for SRPT, as published in its report on November 27, 2024. H.C. Wainwright’s report from November 25, 2024 suggests a price prediction of $80 for SRPT shares, giving the stock a ‘Sell’ rating. Cantor Fitzgerald also rated the stock as ‘Overweight’.
Analysis of Sarepta Therapeutics Inc (SRPT)
Further, the quarter-over-quarter increase in sales is 65.94%, showing a positive trend in the upcoming months.
Sarepta Therapeutics Inc’s future performance can be predicted by a variety of well-rounded types of analysis and research, with equity being one of the most crucial ones. The goal here is to ensure that your current return on equity of 19.71% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 3.18, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can be an extremely valuable indicator of volatility, and SRPT is registering an average volume of 1.92M. On a monthly basis, the volatility of the stock is set at 7.01%, whereas on a weekly basis, it is put at 5.12%, with a gain of 11.37% over the past seven days. Furthermore, long-term investors anticipate a median target price of $149.83, showing growth from the present price of $61.51, which can serve as yet another indication of whether SRPT is worth investing in or should be passed over.
How Do You Analyze Sarepta Therapeutics Inc Shares?
A giant in the Biotechnology market, Sarepta Therapeutics Inc (SRPT) is based in the USA. When comparing Sarepta Therapeutics Inc shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 25.81, there is a growth in quarterly earnings of 272.83%.
Besides checking the fundamentals, you should also know how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 6.07%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 91.99% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
SRPT shares are owned by institutional investors to the tune of 91.99% at present.
